首页> 外文期刊>Journal of arrhythmia. >Prevention of Torsade de Pointes during the Pharmacologic Treatment of Atrial Fibrillation
【24h】

Prevention of Torsade de Pointes during the Pharmacologic Treatment of Atrial Fibrillation

机译:心房颤动的药物治疗中预防尖锐湿疣

获取原文
           

摘要

Potassium channel blockers are sometimes effective in the rhythm management of persistent atrial fibrillation. However, on rare occasions, a life-threatening episode of torsade de pointes develops during treatment with these agents. Among several precautions against this tragedy, preventing exaggerated QT prolongation is of paramount importance. One of the difficulties in monitoring the QT interval during atrial fibrillation is the fact that its length varies depending not only on the fluctuating preceding intervals, but on other factors such as neurohumoral activation. In fact, even at the same preceding RR interval, the QT interval may vary from day to night, between atrial fibrillation and sinus rhythm. Accordingly, the QTc interval may not be a reliable parameter for predicting proarrhythmic events. As the result, close monitoring of the QT interval itself, just like INR monitoring during warfarin treatment, is mandatory both before and during treatment with these agents.
机译:钾通道阻滞剂有时在持续性房颤的节律管理中有效。然而,在极少数情况下,在使用这些药物治疗期间会发生致命的尖端扭转型室速发作。在针对这一悲剧的几种预防措施中,防止夸张的QT延长至关重要。房颤期间监测QT间隔的困难之一是其长度不仅取决于波动的先前间隔,还取决于其他因素(例如神经体液激活)而变化。实际上,即使在相同的先前RR间隔下,QT间隔也可能在昼夜之间变化,在心房颤动和窦性心律之间。因此,QTc间隔可能不是用于预测心律失常事件的可靠参数。结果,就像在华法林治疗期间的INR监测一样,在使用这些药物治疗之前和期间都必须对QT间隔本身进行密切监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号